ICECREAM: Randomised phase II study of cetuximab alone or in combination with irinotecan in patients with metastatic colorectal cancer with either KRAS, NRAS, BRAF and PI3KCA wild type, or G13D mutated tumours

Eva Segelov, Paul Waring, Jayesh Desai, Kate Wilson, Val Gebski, Subotheni Thavaneswaran, Elena Elez, Craig Underhill, Nick Pavlakis, Lorraine Chantrill, Louise Nott, Michael Jefford, Mustafa Khasraw, Fiona Day, Harpreet Wasan, Fortunato Ciardiello, Chris Karapetis, Warren Joubert, Guy van Hazel, Andrew HaydonTim Price, Sabine Tejpar, Niall Tebbutt, Jeremy Shapiro

    Research output: Contribution to journalArticlepeer-review

    9 Citations (Scopus)

    Fingerprint

    Dive into the research topics of 'ICECREAM: Randomised phase II study of cetuximab alone or in combination with irinotecan in patients with metastatic colorectal cancer with either KRAS, NRAS, BRAF and PI3KCA wild type, or G13D mutated tumours'. Together they form a unique fingerprint.

    Medicine & Life Sciences